Medicare and Medicaid
Our work in Medicare and Medicaid
-
Clozapine Revisited: Impact of Clozapine vs Olanzapine on Health Care Use by Schizophrenia Patients on Medicaid
In this evaluation of health care use and cost patterns for clozapine compared with olanzapine in the treatment of schizophrenia, the researchers found that clozapine increased duration of therapy and decreased risk of psychiatric hospitalization or suicide attempts compared to olanzapine, though increased drug costs and use of community mental health centers for complete blood count monitoring overwhelmed any offsetting savings.
Categorized in -
Insurers’ Negotiating Leverage and the External Effects of Medicare Part D
The researchers analyzed how increases in insurer size resulting from the implementation of Medicare Part D affected drug prices negotiated in the non-Medicare commercial market.
Categorized in -
Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States
This study estimated the US incremental cost burden of undiagnosed nonvalvular atrial fibrillation (AF) using administrative claims for working age and Medicare patients, and found that the direct medical costs for patients with undiagnosed AF are significantly higher than patients with similar observable characteristics without AF.
Categorized in -
Undertreatment of Osteoporosis and the Role of Gastrointestinal Events among Elderly Osteoporotic Women with Medicare Part D Drug Coverage
This study examined the rate of osteoporosis (OP) undertreatment and the association between gastrointestinal (GI) events and OP treatment initiation among elderly osteoporotic women with Medicare Part D drug coverage, and found that, among elderly women newly diagnosed with OP, only 28% initiated OP treatment, and GI events were associated with a higher likelihood of not being treated and a lower likelihood of being treated with bisphosphonates versus non-bisphosphonates.
Categorized in -
Did Medicare Part D Reduce Disparities?
This study assessed whether Medicare Part D reduced disparities in access to medication and found that the Part D coverage gap is disruptive to minorities and those living in low-income areas.
Categorized in -
Medicaid Access Restrictions on Psychiatric Drugs: Penny-Wise or Pound-Foolish?
Not only do formulary restrictions save little — if any — money on drug spending, they increase overall Medicaid spending for serious mental illnesses and may drive up incarceration costs.
-
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Categorized in -
Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital?
The researchers analyzed the effects of oral nutritional supplement (ONS) use on 30-day readmission rates, length of stay (LOS), and episode costs in hospitalized Medicare patients (≥65), and subsets of patients diagnosed with acute myocardial infarction (AMI), congestive heart failure (CHF) or pneumonia (PNA), finding that ONS use was associated with improved outcomes and decreased healthcare costs, and is therefore relevant to providers seeking an inexpensive, evidence-based approach for meeting Affordable Care Act quality targets.
Categorized in -
The Growing Gap in Life Expectancy: Using the Future Elderly Model to Estimate Implications for Social Security and Medicare
This paper used the Future Elderly Model to estimate the effects of increased mortality gaps on the progressivity of Social Security and Medicare for those born between 1928 and 1990, and found that significant reductions in progressivity of both programs if current mortality trends persist and noticeable effects on total program costs.
Categorized in -
Quintiles Seminar Series – Spring: Jan-May 2014
The Quintiles Seminar Series is a biweekly seminar series that features prominent academics, researchers, policy makers, and industry leaders to discuss prevalent and current themes in health, policy, and economics.
Categorized in